| Cancers | |
| Clinical Studies on Cytokine-Induced Killer Cells: Lessons from Lymphoma Trials | |
| Hans Weiher1  Amit Sharma2  Ingo G. H. Schmidt-Wolf2  Ying Zhang2  Matthias Schmid3  Glen Kristiansen4  | |
| [1] Department of Applied Natural Sciences, Bonn-Rhein-Sieg University of Applied Sciences, 53359 Rheinbach, Germany;Department of Integrated Oncology, Center for Integrated Oncology (CIO), University Hospital Bonn, 3127 Bonn, Germany;Institute for Medical Biometry, Computer Science and Epidemiology, University Hospital Bonn, 53127 Bonn, Germany;Institute of Pathology, University Hospital Bonn, 53127 Bonn, Germany; | |
| 关键词: lymphoma; cytokine-induced killer cells; clinical study; immunotherapy; | |
| DOI : 10.3390/cancers13236007 | |
| 来源: DOAJ | |
【 摘 要 】
Cancer is a complex disease where resistance to therapies and relapses often pose a serious clinical challenge. The scenario is even more complicated when the cancer type itself is heterogeneous in nature, e.g., lymphoma, a cancer of the lymphocytes which constitutes more than 70 different subtypes. Indeed, the treatment options continue to expand in lymphomas. Herein, we provide insights into lymphoma-specific clinical trials based on cytokine-induced killer (CIK) cell therapy and other pre-clinical lymphoma models where CIK cells have been used along with other synergetic tumor-targeting immune modules to improve their therapeutic potential. From a broader perspective, we will highlight that CIK cell therapy has potential, and in this rapidly evolving landscape of cancer therapies its optimization (as a personalized therapeutic approach) will be beneficial in lymphomas.
【 授权许可】
Unknown